YM155 Restores the Effect of Imatinib in Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
YM155 enhances imatinib's efficacy against both sensitive and resistant CML cells, overcoming resistance through synergistic inhibition of proliferation, increased apoptosis, and suppression of survivin and BCR::ABL1 expression. These results support further investigation of YM155-Imatinib combination therapy as a potential strategy for resistant CML.
Authors
- Mohammad Bani-Ahmad (ORCID: https://orcid.org/0000-0001-5991-8383)
- Belal Al‐Husein (ORCID: https://orcid.org/0000-0003-4001-5058)
- Mohammad A. Y. Alqudah (ORCID: https://orcid.org/0000-0001-7210-7964)
- Rand M. Nofal
Institutions
- Jordan University of Science and Technology (JO)
Publication Details
- Journal
- Current Cancer Drug Targets
- Published
- 2025-10-27
- DOI
- https://doi.org/10.2174/0115680096402329251002224513
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00